论文部分内容阅读
目的探讨恶性肿瘤患者血清内皮素－１（ＥＴ－１）的水平及其临床意义。方法采用放射免疫法，检测了恶性肿瘤患者８５例、非肿瘤患者３０例和正常人３２例血清ＥＴ－１的含量。结果正常人和非肿瘤患者血清ＥＴ－１的平均含量分别为（４６．９ ± ２３．１）μｇ／Ｌ和（５１．１± ３０．９）μｇ／Ｌ，不同恶性肿瘤患者为（１９０．１±１３５．２－３８２．４±１９０．１）μｇ／Ｌ。正常人与非肿瘤患者相比较，血清ＥＴ－１的平均含量无明显差异（Ｐ＞０．０５）；而恶性肿瘤患者血清ＥＴ－１的含量则明显高于前两者（Ｐ＜０．００１）。以正常人血清ＥＴ－１的平均含量加两个标准差为阳性界值，则不同恶性肿瘤患者的阳性检出率为７２％－１００％。结论血清ＥＴ的含量是筛选和辅助诊断恶性肿瘤的一种良好肿瘤标志物。
Objective To investigate the serum endothelin-1 (ET-1) levels in patients with malignant tumors and its clinical significance. Methods Radioimmunoassay was used to detect serum ET-1 levels in 85 patients with malignant tumors, 30 non-tumor patients, and 32 normal controls. Results The mean levels of serum ET-1 in normal and non-tumor patients were (46.9 ± 23.1) μg/L and (51.1 ± 30.9) μg/L, respectively. Patients with different malignant tumors (190. 1±135.2-382.4±190.1) μg/L. There was no significant difference in the mean level of serum ET-1 between normal and non-tumor patients (P>0.05); however, the level of serum ET-1 in malignant tumor patients was significantly higher than the former two (P<0.001). ). The mean positive rate of serum ET-1 plus two standard deviations is the positive boundary value, and the positive detection rate of different malignant tumor patients is 72%-100%. Conclusion The content of serum ET is a good tumor marker for screening and assisting in the diagnosis of malignant tumors.